HROW

Harrow, Inc. (HROW) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This summary covers Harrow, Inc.'s unaudited financial results for the quarterly period ended September 30, 2025. Harrow is a leading provider of ophthalmic disease management solutions in North America, operating through two primary segments: Branded (FDA-approved pharmaceutical products) and ImprimisRx (ophthalmology-focused compounding business). The company reported its first net income in nine months, driven by significant revenue growth in its branded portfolio and a major debt refinancing event.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 45% year-over-year in Q3 2025. The Branded segment drove this growth with revenues of $51.58 million (up 81% YoY), primarily due to increased sales of IHEEZO and VEVYE. The ImprimisRx segment remained relatively flat at $20.06 million.
• Profitability: The company returned to profitability in Q3 2025 with $1.02 million in net income, compared to a net loss of $4.22 million in Q3 2024. Operating income surged to $14.75 million from $1.32 million.
• Debt Restructuring: In September 2025, Harrow closed a private offering of $250 million in 8.625% Senior Notes due 2030. Proceeds were used to fully repay the Oaktree Loan ($107.5M), 2026 Notes ($75M), and 2027 Notes ($40.25M). This resulted in a $7.75 million loss on extinguishment of debt recorded in Q3 2025.
• Segment Margins: Branded gross margin was 81.6% in Q3 2025 (down slightly from 81.9% YoY due to fixed expenses and amortization). ImprimisRx gross margin decreased to 59.0% from 66.9% YoY, attributed to product mix shifts and one-time efficiency costs.

Guidance, Outlook, and Risks

• Strategic Initiatives:
  • Harrow Access For All (HAFA): Launched in September 2025 to unify patient access across the branded, authorized generic, and compounded portfolios.
  • Project Beagle: A 360-degree review to transition ImprimisRx patients from compounded formulations to Harrow-owned FDA-approved products (e.g., transitioning from Klarity-C to VEVYE).
  • Melt Pharmaceuticals Acquisition: Entered a merger agreement in September 2025 to acquire remaining interests in Melt Pharmaceuticals. Closing is expected in Q4 2025, with potential contingent consideration up to $261 million in cash plus equity upon achieving sales milestones.
• Liquidity: Management believes cash on hand ($74.29M) plus operating cash flow will sustain operations for at least 12 months. A new $40 million revolving credit facility with Fifth Third Bank was established but remains undrawn.
• Risks and Contingencies:
  • Regulatory: Ongoing FDA interactions regarding the New Jersey outsourcing facility (NJOF). While the FDA allowed voluntary remediation to continue, there are risks of license denial or restrictions. An administrative accusation by the California State Board of Pharmacy is also pending.
  • Legal: A $11.25 million judgment against Ocular Science, Inc. (OSRX) was finalized in October 2025; collection efforts are ongoing but not recognized in financials due to uncertainty.
  • Government Shutdown: A U.S. government shutdown beginning October 1, 2025, poses risks to FDA review timelines, CMS reimbursement guidance, and SEC filing reviews.

Investor Verification Checklist

• Verify the status of the Melt Pharmaceuticals merger closing and the specific terms of the contingent consideration ($87.2M cash upon FDA approval).
• Monitor the outcome of the FDA remediation efforts at the New Jersey outsourcing facility and the California State Board of Pharmacy administrative action.
• Assess the collectability of the $11.25 million OSRX judgment and any potential impact on future legal accruals.
• Review the impact of the 8.625% Senior Notes on future interest expense and fixed charge coverage ratios under the new Fifth Third credit facility.
• Track the execution of Project Beagle to ensure successful transition of compounded patients to branded products without significant revenue erosion.